Home › Companies › Olema Pharmaceuticals, Inc. › 2025-2026

Olema Pharmaceuticals, Inc. 2025-2026 Proxy Voting Records

Compiled from SEC Form N-PX filings and Olema Pharmaceuticals, Inc.’s Form 8-K, filed 2026-06-23 (Item 5.07 on EDGAR). Page generated 02 October 2026.

8Reported items
219Asset managers
1,519Fund votes
2026-06-17Meeting date

Proxy season: 2023-2024 2024-2025 2025-2026

Explore Olema Pharmaceuticals, Inc. in the interactive database Compare manager voting policies

Official 2025-2026 meeting results reported by Olema Pharmaceuticals, Inc.

These tallies are Olema Pharmaceuticals, Inc.’s own, as disclosed to the U.S. Securities and Exchange Commission on Form 8-K, filed 2026-06-23 (Item 5.07, “Submission of Matters to a Vote of Security Holders”). They cover every share voted at the meeting, not just the funds that file Form N-PX.

Olema Pharmaceuticals, Inc. — official shareholder meeting results, meeting held 2026-06-17
Ballot item	For	Against	Abstain	Withheld	Broker non-votes	Outcome
Elect Director: Sean Bohen, M.D., Ph.D.	67,474,365	--	--	1,165,382	7,496,139	Majority: yes
Elect Director: Scott Garland	66,184,382	--	--	2,455,365	7,496,139	Majority: yes
Elect Director: Yi Larson	50,371,668	--	--	18,268,079	7,496,139	Majority: yes
Elect Director: Andrew Rappaport	67,276,575	--	--	1,363,172	7,496,139	Majority: yes
Proposal 2: Advisory Vote on Executive Compensation Final Voting Results	67,969,902	653,979	15,867	--	7,496,139	Majority: yes
Proposal 3: Ratification of Selection of Independent Registered Public Accounting Firm Final Voting Results	75,811,449	271,918	52,520	--	--	Majority: yes

Source: Olema Pharmaceuticals, Inc., Form 8-K, filed with the SEC on 2026-06-23 — read the filing on EDGAR.

How asset managers voted at the Olema Pharmaceuticals, Inc. 2025-2026 meeting

Each item below shows how the 219 asset managers that disclosed a Olema Pharmaceuticals, Inc. vote in their SEC Form N-PX filings actually voted. Share totals are the shares those managers' funds voted, summed across every fund they report. These are reported items, not a count of the ballot: fund filings describe one ballot item in different words. Two descriptions are shown as one item only on evidence — the same text (or one cut short of the other), the same director nominee, or a match to the same row of Olema Pharmaceuticals, Inc.’s own Form 8-K tally — never because they merely read alike. A description that could not be joined that way is listed on its own, so one ballot item can appear more than once.

1. Approval, on an advisory basis, of the compensation of the Company's named executive officers.

SECTION 14A SAY-ON-PAY VOTESMajority of the votes cast: yes

Combines 3 wordings of this item as funds reported it.

99.0% Majority: yes · of votes cast

FOR 99.0%

FOR: 67,969,902AGAINST: 653,979

Olema Pharmaceuticals, Inc.’s own tally for this item (“Proposal 2: Advisory Vote on Executive Compensation Final Voting Results”): 67,969,902 for, 653,979 against, per its Form 8-K filed 2026-06-23 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 87,332,971 outstanding shares: 78% for, 0.8% against (79% of the company cast a for/against vote).

The 213 asset managers below cast 99% of the shares they voted on this item FOR. Fund share totals are not shown for this item: fund-reported shares overlap across filings (an adviser and the funds it manages can each report the same shares), and here their sum exceeds the total votes cast at the meeting.

FOR 99%

FOR: 98.7%AGAINST: 1.3%ABSTAIN: 0.0%NOT VOTED: 0.0%

Largest asset managers voting on “Approval, on an advisory basis, of the compensation of the Company's named executive officers.” at Olema Pharmaceuticals, Inc., 2025-2026
Asset manager	For	Against	Vote
Fidelity	20,293,448	0	For
Janus Henderson	8,083,246	0	For
Paradigm Biocapital Advisors LP	7,387,705	0	For
BVF INC/IL	5,295,893	0	For
Siren, L.L.C.	4,856,949	0	For
Vanguard	4,133,815	3	For
State Street	3,943,182	10,012	For
BlackRock	3,916,749	25,976	For
Polar Capital Holdings Plc	3,205,940	0	For
GEODE CAPITAL MANAGEMENT, LLC	1,578,573	0	For
T. Rowe Price	1,450,415	0	For
FRANKLIN ADVISERS INC	1,448,207	0	For
Logos Global Management LP	1,371,127	0	For
Cormorant Asset Management, LP	1,350,094	0	For
JENNISON ASSOCIATES LLC	1,058,739	0	For
Duquesne Family Office LLC	986,827	0	For
JANUS INVESTMENT FUND	960,580	0	For
Charles Schwab	932,957	0	For
Victory Capital	904,356	0	For
KINGDON CAPITAL MANAGEMENT, L.L.C.	855,000	0	For
FRANKLIN STRATEGIC SERIES	761,941	0	For
Prudential/PGIM	743,815	60	For
Candriam S.C.A.	0	737,513	Against
Vivo Capital, LLC	671,843	0	For
Dimensional	494,323	0	For

Showing the 25 largest of 213 asset managers. See all 213 in the interactive database.

2. Ratification of the selection by the Audit Committee of the Board of Directors of Ernst & Young LLP as the Company's independent registered public accounting firm for the year ending December 31, 2026.

AUDIT-RELATEDMajority of the votes cast: yes

Combines 2 wordings of this item as funds reported it.

99.6% Majority: yes · of votes cast

FOR 99.6%

FOR: 75,811,449AGAINST: 271,918

Olema Pharmaceuticals, Inc.’s own tally for this item (“Proposal 3: Ratification of Selection of Independent Registered Public Accounting Firm Final Voting Results”): 75,811,449 for, 271,918 against, per its Form 8-K filed 2026-06-23 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 87,332,971 outstanding shares: 87% for, 0.4% against (87% of the company cast a for/against vote).

The 61 asset managers below cast 100% of the shares they voted on this item FOR (24,872,993 for, 0 against).

FOR 100%

FOR: 24,872,993 (100.0%)

Largest asset managers voting on “Ratification of the selection by the Audit Committee of the Board of Directors of Ernst & Young LLP as the Com” at Olema Pharmaceuticals, Inc., 2025-2026
Asset manager	For	Vote
Fidelity	10,291,314	For
Vanguard	3,692,256	For
State Street	2,732,320	For
BlackRock	2,237,083	For
JANUS INVESTMENT FUND	960,580	For
FRANKLIN STRATEGIC SERIES	761,941	For
Prudential/PGIM	689,629	For
T. Rowe Price	634,370	For
Charles Schwab	466,447	For
Victory Capital	444,083	For
Dimensional	351,809	For
TIAA	132,618	For
QUANTITATIVE MASTER SERIES LLC	113,504	For
Equitable	103,304	For
Voya	99,199	For
Tema ETF Trust	80,791	For
Lincoln Financial	77,125	For
American Century	74,863	For
ALPS ETF Trust	71,898	For
ProShares	70,674	For
JPMorgan	65,964	For
Putnam	59,605	For
Delaware/Macquarie	50,000	For
AIG/SunAmerica	48,698	For
Franklin Alternative Strategies Funds	42,319	For

Showing the 25 largest of 61 asset managers. See all 61 in the interactive database.

3. Election of the four nominees for Class III director named in the accompanying proxy statement to hold office until the Company's 2029 Annual Meeting of Stockholders and until their successors have been duly elected and qualified: Sean Bohen, M.D., Ph.D.

DIRECTOR ELECTIONSMajority of the votes cast: yes

Combines 6 wordings of this item as funds reported it.

98% Majority: yes · of votes cast

FOR 98%

FOR: 67,474,365WITHHELD: 1,165,382

Olema Pharmaceuticals, Inc.’s own tally for this item (“Elect Director: Sean Bohen, M.D., Ph.D.”): 67,474,365 for, 1,165,382 withheld, per its Form 8-K filed 2026-06-23 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 87,332,971 outstanding shares: 77% for, 1% withheld (79% of the company cast a for/withheld vote).

The 60 asset managers below cast 100% of the shares they voted on this item FOR (24,395,814 for, 0 against).

FOR 98%

FOR: 24,395,814 (98.4%)ABSTAIN: 392,541 (1.6%)

Largest asset managers voting on “Election of the four nominees for Class III director named in the accompanying proxy statement to hold office ” at Olema Pharmaceuticals, Inc., 2025-2026
Asset manager	For	Abstain	Vote
Fidelity	10,291,314	0	For
Vanguard	3,687,463	4,793	For
State Street	2,728,720	3,600	For
BlackRock	2,237,083	0	For
JANUS INVESTMENT FUND	960,580	0	For
FRANKLIN STRATEGIC SERIES	761,941	0	For
Prudential/PGIM	685,545	4,084	For
T. Rowe Price	634,370	0	For
Charles Schwab	466,447	0	For
Victory Capital	444,083	0	For
Dimensional	0	351,809	Abstain
TIAA	132,618	0	For
QUANTITATIVE MASTER SERIES LLC	113,504	0	For
Equitable	103,304	0	For
Voya	99,199	0	For
Tema ETF Trust	80,791	0	For
Lincoln Financial	71,451	5,674	For
American Century	74,863	0	For
ALPS ETF Trust	71,898	0	For
ProShares	70,674	0	For
JPMorgan	65,964	0	For
Delaware/Macquarie	50,000	0	For
AIG/SunAmerica	48,698	0	For
Goldman Sachs	41,303	0	For
MFS	39,018	0	For

Showing the 25 largest of 60 asset managers. See all 60 in the interactive database.

4. Election of the four nominees for Class III director named in the accompanying proxy statement to hold office until the Company's 2029 Annual Meeting of Stockholders and until their successors have been duly elected and qualified: Scott Garland

DIRECTOR ELECTIONSMajority of the votes cast: yes

Combines 6 wordings of this item as funds reported it.

96% Majority: yes · of votes cast

FOR 96%

FOR: 66,184,382WITHHELD: 2,455,365

Olema Pharmaceuticals, Inc.’s own tally for this item (“Elect Director: Scott Garland”): 66,184,382 for, 2,455,365 withheld, per its Form 8-K filed 2026-06-23 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 87,332,971 outstanding shares: 76% for, 3% withheld (79% of the company cast a for/withheld vote).

The 60 asset managers below cast 100% of the shares they voted on this item FOR (24,131,081 for, 0 against).

FOR 97%

FOR: 24,131,081 (97.3%)ABSTAIN: 657,274 (2.7%)

Largest asset managers voting on “Election of the four nominees for Class III director named in the accompanying proxy statement to hold office ” at Olema Pharmaceuticals, Inc., 2025-2026
Asset manager	For	Abstain	Vote
Fidelity	10,291,314	0	For
Vanguard	3,692,249	7	For
State Street	2,732,320	0	For
BlackRock	2,237,083	0	For
JANUS INVESTMENT FUND	960,580	0	For
FRANKLIN STRATEGIC SERIES	761,941	0	For
Prudential/PGIM	685,545	4,084	For
T. Rowe Price	634,370	0	For
Charles Schwab	466,447	0	For
Victory Capital	444,083	0	For
Dimensional	0	351,809	Abstain
TIAA	132,618	0	For
QUANTITATIVE MASTER SERIES LLC	113,504	0	For
Equitable	65,924	37,380	For
Voya	0	99,199	Abstain
Tema ETF Trust	80,791	0	For
Lincoln Financial	71,451	5,674	For
American Century	74,863	0	For
ALPS ETF Trust	71,898	0	For
ProShares	70,674	0	For
JPMorgan	65,964	0	For
Delaware/Macquarie	0	50,000	Abstain
AIG/SunAmerica	48,698	0	For
Goldman Sachs	37,184	4,119	For
MFS	0	39,018	Abstain

Showing the 25 largest of 60 asset managers. See all 60 in the interactive database.

5. Election of the four nominees for Class III director named in the accompanying proxy statement to hold office until the Company's 2029 Annual Meeting of Stockholders and until their successors have been duly elected and qualified: Yi Larson

DIRECTOR ELECTIONSMajority of the votes cast: yes

Combines 6 wordings of this item as funds reported it.

73% Majority: yes · of votes cast

FOR 73%WITHHELD 27%

FOR: 50,371,668WITHHELD: 18,268,079

Olema Pharmaceuticals, Inc.’s own tally for this item (“Elect Director: Yi Larson”): 50,371,668 for, 18,268,079 withheld, per its Form 8-K filed 2026-06-23 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 87,332,971 outstanding shares: 58% for, 21% withheld (79% of the company cast a for/withheld vote).

The 60 asset managers below cast 100% of the shares they voted on this item FOR (20,488,431 for, 0 against).

FOR 83%ABSTAIN 17%

FOR: 20,488,431 (82.7%)ABSTAIN: 4,299,924 (17.3%)

Largest asset managers voting on “Election of the four nominees for Class III director named in the accompanying proxy statement to hold office ” at Olema Pharmaceuticals, Inc., 2025-2026
Asset manager	For	Abstain	Vote
Fidelity	10,291,314	0	For
Vanguard	3,685,089	7,167	For
State Street	2,003	2,730,317	Abstain
BlackRock	2,237,083	0	For
JANUS INVESTMENT FUND	960,580	0	For
FRANKLIN STRATEGIC SERIES	761,941	0	For
Prudential/PGIM	685,545	4,084	For
T. Rowe Price	634,370	0	For
Charles Schwab	466,447	0	For
Victory Capital	0	444,083	Abstain
Dimensional	0	351,809	Abstain
TIAA	132,618	0	For
QUANTITATIVE MASTER SERIES LLC	113,504	0	For
Equitable	65,924	37,380	For
Voya	0	99,199	Abstain
Tema ETF Trust	80,791	0	For
Lincoln Financial	0	77,125	Abstain
American Century	0	74,863	Abstain
ALPS ETF Trust	0	71,898	Abstain
ProShares	0	70,674	Abstain
JPMorgan	65,964	0	For
Delaware/Macquarie	0	50,000	Abstain
AIG/SunAmerica	0	48,698	Abstain
Goldman Sachs	41,303	0	For
MFS	0	39,018	Abstain

Showing the 25 largest of 60 asset managers. See all 60 in the interactive database.

6. Election of the four nominees for Class III director named in the accompanying proxy statement to hold office until the Company's 2029 Annual Meeting of Stockholders and until their successors have been duly elected and qualified: Andrew Rappaport

DIRECTOR ELECTIONSMajority of the votes cast: yes

Combines 6 wordings of this item as funds reported it.

98% Majority: yes · of votes cast

FOR 98%

FOR: 67,276,575WITHHELD: 1,363,172

Olema Pharmaceuticals, Inc.’s own tally for this item (“Elect Director: Andrew Rappaport”): 67,276,575 for, 1,363,172 withheld, per its Form 8-K filed 2026-06-23 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 87,332,971 outstanding shares: 77% for, 2% withheld (79% of the company cast a for/withheld vote).

The 60 asset managers below cast 100% of the shares they voted on this item FOR (24,358,353 for, 0 against).

FOR 98%

FOR: 24,358,353 (98.3%)ABSTAIN: 430,002 (1.7%)

Largest asset managers voting on “Election of the four nominees for Class III director named in the accompanying proxy statement to hold office ” at Olema Pharmaceuticals, Inc., 2025-2026
Asset manager	For	Abstain	Vote
Fidelity	10,291,314	0	For
Vanguard	3,687,463	4,793	For
State Street	2,728,639	3,681	For
BlackRock	2,237,083	0	For
JANUS INVESTMENT FUND	960,580	0	For
FRANKLIN STRATEGIC SERIES	761,941	0	For
Prudential/PGIM	685,545	4,084	For
T. Rowe Price	634,370	0	For
Charles Schwab	466,447	0	For
Victory Capital	444,083	0	For
Dimensional	0	351,809	Abstain
TIAA	132,618	0	For
QUANTITATIVE MASTER SERIES LLC	113,504	0	For
Equitable	65,924	37,380	For
Voya	99,199	0	For
Tema ETF Trust	80,791	0	For
Lincoln Financial	71,451	5,674	For
American Century	74,863	0	For
ALPS ETF Trust	71,898	0	For
ProShares	70,674	0	For
JPMorgan	65,964	0	For
Delaware/Macquarie	50,000	0	For
AIG/SunAmerica	48,698	0	For
Goldman Sachs	41,303	0	For
MFS	39,018	0	For

Showing the 25 largest of 60 asset managers. See all 60 in the interactive database.

7. 14A Executive Compensation

SECTION 14A SAY-ON-PAY VOTESMajority of the votes cast: yes

Combines 3 wordings of this item as funds reported it.

99.0% Majority: yes · of votes cast

FOR 99.0%

FOR: 67,969,902AGAINST: 653,979

The 4 asset managers below cast 100% of the shares they voted on this item FOR (2,666,277 for, 0 against).

FOR 100%

FOR: 2,666,277 (100.0%)

Largest asset managers voting on “14A Executive Compensation” at Olema Pharmaceuticals, Inc., 2025-2026
Asset manager	For	Vote
Bain Capital Life Sciences Investors, LLC	2,666,019	For
PEDDOCK CAPITAL ADVISORS, LLC	250	For
MQS Management LLC	8	For
Ikarian Capital, LLC	0	--

8. Election of the four nominees for Class IIl director named in the accompanying proxy statement to hold office until the Company's 2029 Annual Meeting of Stockholders and until their successors have been duly elected and qualified.

DIRECTOR ELECTIONS

100% fund support · no official result

FOR 100%

The 2 asset managers below cast 100% of the shares they voted on this item FOR (84,638 for, 0 against).

FOR: 84,638 (100.0%)

Largest asset managers voting on “Election of the four nominees for Class IIl director named in the accompanying proxy statement to hold office ” at Olema Pharmaceuticals, Inc., 2025-2026
Asset manager	For	Against	Abstain	Withheld	Vote
Franklin Alternative Strategies Funds	42,319	0	0	0	For
Putnam	42,319	0	0	0	For

Largest Olema Pharmaceuticals, Inc. shareholders voting in 2025-2026

Ranked by the number of Olema Pharmaceuticals, Inc. shares each manager voted on the most widely held ballot item of the 2025-2026 meeting, shown as a share of the 87,332,971 shares outstanding at the time of that meeting.

Top Olema Pharmaceuticals, Inc. shareholders by shares voted, 2025-2026
#	Asset manager	% of shares outstanding
1	Fidelity	23.24%
2	Janus Henderson	9.26%
3	Paradigm Biocapital Advisors LP	8.46%
4	BVF INC/IL	6.06%
5	Siren, L.L.C.	5.56%
6	Vanguard	4.73%
7	State Street	4.53%
8	BlackRock	4.51%
9	Polar Capital Holdings Plc	3.67%
10	GEODE CAPITAL MANAGEMENT, LLC	1.81%

Reported Olema Pharmaceuticals, Inc. ownership

Positions disclosed to the SEC on Schedules 13D and 13G, Form 13F and the company’s own proxy statement (DEF 14A).

Olema Pharmaceuticals, Inc. beneficial owners on record for the 2025-2026 proxy season
Holder	% outstanding	Disclosure
FMR (Fidelity)	11.89%	13F
JANUS HENDERSON GROUP PLC	8.14%	13G
BlackRock	6.47%	13F
Raymond Debbane	5.11%	13G
State Street	4.51%	13F
Vanguard Group	4.08%	13F
Geode Capital	1.77%	13F
Goldman Sachs	1.43%	13F
Franklin Templeton	1.40%	13F
T. Rowe Price	1.35%	13F

Percentages above are of 87,332,971 shares outstanding, as reported by Olema Pharmaceuticals, Inc. on its Form 10-Q dated 2026-03-31 (see the filing on EDGAR). This is the count contemporaneous with the 2025-2026 meeting, so the percentages are the ones that were true then, not ones restated against today’s share count.

About this page

Every figure above is derived from filings made with the US Securities and Exchange Commission: Form N-PX, in which registered investment companies and institutional managers disclose how they voted every proxy, and Form 8-K Item 5.07, in which the company reports its own meeting results. Shares outstanding are taken from Olema Pharmaceuticals, Inc.’s 10-Q dated 2026-03-31. This page is a static snapshot rebuilt weekly on 02 October 2026; a live search always shows the current data.

At Olema Pharmaceuticals, Inc.'s shareholder meeting held 2026-06-17, in the 2025-2026 proxy season, 219 asset managers reported how they voted in their SEC Form N-PX filings, covering 1,519 separate fund positions. Their filings are grouped here into 8 reported items; because filers word the same ballot item differently, that can be more than the number of items on the ballot. On the most widely held item on that ballot — Approval, on an advisory basis, of the compensation of the Company's named executive officers. — FOR was 99.0% of the votes cast (FOR divided by FOR plus AGAINST, the conventional basis for proxy support; abstentions, broker non-votes and unvoted shares are excluded because none of them took a side), which is more than half. Whether the item was approved is for the filing to say; that statement has not been read for this item. Source: Olema Pharmaceuticals, Inc.'s Form 8-K, Item 5.07, filed with the U.S. Securities and Exchange Commission on 2026-06-23.

Olema Pharmaceuticals, Inc. proxy season coverage: 2023-2024 · 2024-2025 · 2025-2026 (this page).